EGFR and lung adenocarcinoma: Four hundred and twenty-two patients with EGFR mutation-positive advanced lung adenocarcinoma received gefitinib (n = 195), erlotinib (n = 123), or afatinib (n = 104) as first-line treatment (Figure 1).